Clinical Trial Update: A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

View source ↗

Summary

Completed trial evaluating tocilizumab in active rheumatoid arthritis patients with an inadequate response to non-biologic DMARDs; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2016-12-01